MSK-IMPACT® Flex powered with SOPHiA DDM™

SKU: BS0132ILLRSMY13-16

0.00 NIS

Quote Required

In stock

Optimize lab efficiency with a modular solution built on the expertly curated MSK-IMPACT® content, covering 533 DNA genes and 140 RNA genes, with the option to add RNA and HRD analysis at a sample level. Learn More >

Sample-to-report bundle: capture-based target enrichment and library preparation kit combined with the analytical capabilities of the SOPHiA DDM™ Platform.

Specifications

Gene content	533 DNA (incl. 505 genes from MSK-IMPACT®) 140 RNA
Diseases covered	Multi-cancer (any solid tumor)
Detected variants	From DNA: SNVs/Indels in 533 genes Whole gene amplifications and deletions in 520 genes Gene-level and exon-level CNVs in 49 genes TERT promoter TMB MSI HRD (optional) From RNA: Partner-agnostic fusions in 135 genes Exon skipping events in 9 genes Gene expression in 56 genes
Sample type	FFPE, fresh-frozen
Starting material	50 ng DNA (min. 10 ng), 50 ng RNA (min. 10 ng)
Sequencer compatibility	Illumina® NextSeq® 550/1000/2000 Illumina® NovaSeq™ 6000, X Compatible with MGI and Element sequencers
Library preparation time	1.5 days (DNA only) 2 days (DNA+RNA)
Analysis time from FASTQ	DNA only – <10 hours DNA + RNA – <15 hours
Regulatory status	Research Use Only (RUO)
Application Type	Bundle (sample-to-report)
Limit of detection at 95% (LOD95)	5%
Recommended paired-end reads	DNA capture – 51 million RNA capture – 11 million DNA whole genome sequencing (at ~1x coverage) – 20 million

Flexible CGP analysis without compromise

Achieve scalable analysis of solid tumors with an agile and modular approach to comprehensive genomic profiling (CGP), eliminating the need for multiple tests.

Built on the expert-designed content of MSK-IMPACT® and combined with the adaptive analytics of the SOPHiA DDM™ Platform, MSK-IMPACT® Flex powered with SOPHiA DDM™ delivers high-resolution profiling of complex biomarkers from DNA and RNA in a single, end-to-end workflow.

Expert content design – Built on the backbone of MSK-IMPACT®, curated by Memorial Sloan Kettering Cancer Center (MSK) experts and verified in over 1,000 MSK publications.

In-depth CNV detection – Gain high-resolution profiling of gene and exon-level CNVs, with genome-wide copy number context.

Comprehensive profiling – Detect all major variant classes (SNVs/Indels, CNVs, partner-agnostic fusions, exon-skipping events, gene expression) and complex signatures (TMB, MSI, HRD).

Maximized lab efficiency – Reduce turnaround time by eliminating send-outs and covering DNA and RNA analysis in a single, automated workflow.

Modular analysis – Add RNA and HRD analysis at the sample level to tailor biomarker coverage, reducing unecessary testing.

Enhanced interpretation – Navigate variant interpretation at every level, from individual alterations to broader clinical context, with OncoPortal™ Knowledge Base.

Streamline your workflow

Boost lab efficiency with a single, streamlined, end-to-end NGS workflow that allows you to analyze multiple data modalities in one sequencing run. All variant detection and interpretation steps are powered by the SOPHiA DDM™ Platform, giving you full control over your data and samples.

Advancing precision oncology – your way – The modular architecture of the SOPHiA DDM™ Platform enables a truly flexible approach to CGP. You can easily integrate analytical modules – DNA capture, RNA capture and/or low-pass whole-genome sequencing analysis – at the sample level. This approach allows you to tailor workflows to your institution’s specific needs and deliver the most relevant insights for every case.

Take your research further by complementing your tissue analysis with SOPHiA DDM™ for Liquid Biopsy, enabling advanced monitoring of resistance and a comprehensive view of the tumor landscape.

Documents

Ordering Information

Product code	Sequencer	Reactions
BS0132ILLRSMY13-16	Illumina	16
BS0132ILLRSMY13-32	Illumina	32
BS0132ILLRSMY13-48	Illumina	48
BS0132ILLRSMY13-96	Illumina	96
BS0132MGIRSMY13-16	MGI	16
BS0132MGIRSMY13-32	MGI	32
BS0132MGIRSMY13-48	MGI	48
BS0132MGIRSMY13-96	MGI	96

For Research Use Only. Not for use in diagnostic procedures.

Specifications

Assay time DNA only – <10 hours; DNA + RNA – <15 hours
Cancer type Multi-cancer (any solid tumor)
Content specifications 533 DNA (incl. 505 genes from MSK-IMPACT®); 140 RNA
Hands on time 1.5 days (DNA only); 2 days (DNA+RNA)
Input quantity 50 ng DNA (min. 10 ng), 50 ng RNA (min. 10 ng)
Instruments Illumina® NextSeq® 550/1000/2000Illumina® NovaSeq™ 6000, XCompatible with MGI and Element sequencers
Pack size 16, 32, 48, 96 reactions
Regulations Research Use Only (RUO)
Specialized sample types FFPE, fresh-frozen
Sub category CGP
Variant class From DNA:; SNVs/Indels in 533 genes; Whole gene amplifications and deletions in 520 genes; Gene-level and exon-level CNVs in 49 genes; TERT promoter; TMB; MSI; HRD (optional); From RNA:; Partner-agnostic fusions in 135 genes

links and documants

Brochure url Click here
Datasheet url Click here
Source url Click here